Navigation Links
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
Date:3/25/2009

pharma.com" target="_new">http://www.novabaypharma.com Passcode: 48544871 To access audio replay: Access # (U.S.): 888-286-8010 Access # (International): 617-801-6888 Replay Passcode: 94169247

About Aganocide Compounds

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically designed by NovaBay to mimic the body's natural defense against infection. These compounds may deliver the same or better efficacy as currently used antibiotics without contributing to the growing rise of bacterial resistance. This new class of highly differentiated compounds is ideally suited to meet numerous unmet needs in dermatology and other applications, while currently available therapies do not provide adequate treatment and often cause unwanted side effects. The Aganocide compounds have shown in preclinical trials to date to be highly effective against the bacteria, viruses and fungi associated with a wide range of dermatological and other conditions. They have also been demonstrated to be effective against bacteria in biofilm, which render most antibiotics ineffective. The combined anti-bacterial and anti-fungal properties and activity of these compounds make them uniquely able to address the multi-factorial causes of many skin and other disorders. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability and dosing versatility and flexibility.

About Acne

Acne is the most common skin disease that affects people of all races and age-groups, but it is most common in teenagers and young adults. An estimated 80 percent of all people between the ages of 11 and 30 suffer from outbreaks of acne at some point, and some people in their forties and fifties are also affected. There is a clear need for more effective antimicrobial treatments than the currently available antibi
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
2. Galderma Completes Acquisition of CollaGenex
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
6. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
7. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
8. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
9. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
10. Neogen Acquires Kane Enterprises
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 One of the major revolutions taking ... which is the practice of using genomic and other ... individual biology. Personalized diagnostics—laboratory analyses that inform the practice ... lab,s future. This fall, AACC ,s first ever ... in this exciting field and the novel technologies driving ...
(Date:8/1/2014)... 1, 2014 According to a ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 25.16 billion in 2013, which is expected ... a CAGR of 10.4% from 2014 to 2020. ... Increasing demand for accurate early diagnosis ...
(Date:8/1/2014)... Once a decision has been made to ... discuss how to define your tolerance for lowest cost ... Senior Director of Facilities Integration at Fluor Industrial Services, ... Services, and special guest Carrier Li, Director in Global ... they provide an examination of the Conceptual Design process ...
(Date:8/1/2014)... 2014 Cambrex Corporation (NYSE: CBM ) ... Highlights , Second quarter sales ... same period last year. , Second quarter EBITDA increased ... same period last year (see table at the end of ... excluding the impact of foreign currency, to between 13% and ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... 28 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt Stock Exchange: EVT) ... year ended December 31, 2007., Financial results ... in the,Company,s clinical pipeline and four major corporate ... Technologies (ET), the sale of,the Chemical Development Business ...
... CHAMPAIGN, Ill. Finding a simple and convenient ... identification has been an elusive goal. With current ... ratio too poor, sample preparation too complex or ... service., Now, researchers at the University of Illinois ...
... March 27 Local biotechnology leader,MedImmune announced ... Yiwei Li,has received the distinguished "MedImmune Advancing ... project. The company sponsored the,Montgomery County science ... and presented the award to recognize the ...
Cached Biology Technology:Evotec Announces Financial Results for 2007 2Evotec Announces Financial Results for 2007 3Evotec Announces Financial Results for 2007 4Evotec Announces Financial Results for 2007 5Evotec Announces Financial Results for 2007 6Evotec Announces Financial Results for 2007 7Evotec Announces Financial Results for 2007 8Femtogram-level chemical measurements now possible, U. of I. team reports 2Seneca Valley High School Student Receives Science Award From MedImmune 2Seneca Valley High School Student Receives Science Award From MedImmune 3
(Date:7/31/2014)... research, supported by the National Science Foundation (NSF), ... uniformly accelerates atmospheric warming, indicating instead that certain ... emit into the atmosphere. , The study, ... , focuses on thermokarst lakes, which occur as ... with melted fresh water, converting what was previously ...
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... CHURCH, Va., Feb. 2 CSC (NYSE: ... 12 contractors awarded a Biometrics Operations and Support Services ... Biometrics Task Force (BTF). The indefinite-delivery/indefinite-quantity (IDIQ) contract covers ... to meet the mission needs of BTF business and ...
... 25 percent of eligible African-American adolescents have received the ... Association for Cancer Research conference on the Science of ... of the treatment and might respond to more education. ... funding research to develop ways to increase the rate ...
... University is tracking the movement of the Redbay Ambrosia beetle, ... may severely affect the production of avocados, a $15 million ... in the United States near Savannah, Ga., in 2002, the ... causing widespread mortality in Redbay trees. Dr. Frank Koch, a ...
Cached Biology News:CSC Awarded Department of Defense Biometrics Contract 2African-Americans aware and accepting, but often do not receive, the HPV vaccine 2Holy guacamole: invasive beetle threatens Florida's avocados 2
...
...
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
Biology Products: